TAK
NYSETakeda Pharmaceutical Company Limited
News · 26 weeks78-23%
2025-12-282026-06-21
Mix4190d
- SEC Filings15(37%)
- Insider13(32%)
- Other10(24%)
- Earnings2(5%)
- Analyst1(2%)
Latest news
25 items- PRTakeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment ExpectationsOnce-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis studyMore than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinibSafety profile was consistent with previous studies with no new safety signals identifiedTORONTO, June 23, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2
- SECSEC Form IRANNOTICE filed by Takeda Pharmaceutical Company LimitedIRANNOTICE - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 20-F filed by Takeda Pharmaceutical Company Limited20-F - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- PRNew Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms - Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review Takeda ((TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that
- PRTakeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment ExpectationsOnce-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda ((TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with
- PRU.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's DiseaseIf approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease Potential for ENTYVIO to address pediatric treatment gaps, reflecting Takeda's commitment to advancing options where unmet treatment needs remain Takeda ((TAK) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for intravenous (IV) ENTYVIO® (vedolizumab) for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn's disease in pediatric patients ages 2 years and older. If approved, ENTYVIO would be the onl
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form SD filed by Takeda Pharmaceutical Company LimitedSD - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- SECSEC Form 6-K filed by Takeda Pharmaceutical Company Limited6-K - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Filer)
- PRTakeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 ResultsFY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance Takeda is Entering a New Era & Transforming for Growth Acceleration Takeda ((4502, NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was partially mitigated by Growth and Launch
- PRBritish Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel SyndromeTORONTO, May 5, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") announced that REVESTIVE® (teduglutide for injection) will now be reimbursed by BC PharmaCare for eligible pediatric and adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support.1 Coverage is subject to specific criteria.2 For people living with SBS, reimbursed access can help reduce reliance on parenteral support, which includes intravenous administration of nutrition, fluids, and electrolytes."We welcome the Government of B.C.'s decision to reimburse REVESTIVE for people living with Short
- INSIDERSEC Form 3 filed by new insider Smoter Jennifer Marie3 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- PRTakeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda ((TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrate
- INSIDERPresident and CEO Weber Christophe Pierre was granted 78,900 units of Ordinary Shares and was granted 165,370 units of American Depositary Shares, decreasing direct ownership by 55% to 418,803 units (SEC Form 4) to cover taxes4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
- INSIDERPresident, R&D Plump Andrew Stewart was granted 212,470 units of American Depositary Shares, increasing direct ownership by 36% to 806,572 units (SEC Form 4)4 - TAKEDA PHARMACEUTICAL CO LTD (0001395064) (Issuer)
TAK FAQ
7 questionsWhat does Takeda Pharmaceutical Company Limited do?
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD...Where does TAK stock trade?
Takeda Pharmaceutical Company Limited (TAK) is listed on NYSE.What sector and industry is TAK in?
Takeda Pharmaceutical Company Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Takeda Pharmaceutical Company Limited go public?
Takeda Pharmaceutical Company Limited (TAK) completed its IPO in 2018.What are analysts saying about TAK?
Takeda Pharmaceutical Company Limited has had 6 recent analyst actions on file. The most recent action was from Bernstein: Outperform on 2026-04-08. Recent price targets range from $2000.00 to $2400.00.What companies are similar to TAK?
Notable peers in the same industry include AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), AMGN (Amgen Inc.), BMY (Bristol-Myers Squibb Company), SNY (Sanofi). Compare TAK side-by-side with any of them on Quantisnow.How can I track TAK on Quantisnow?
Quantisnow aggregates Takeda Pharmaceutical Company Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TAK to receive live email and push alerts on every new disclosure.